FDA Approves Tryngolza as Adjunct to Diet for Familial Chylomicronemia Syndrome

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, Dec. 27, 2024 -- Tryngolza (olezarsen) has been approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), which can lead to potentially life-threatening acute pancreatitis (AP), according to a press release issued by Ionis Pharmaceuticals.

Data have shown Tryngolza significantly and substantially reduces triglyceride levels in adults with FCS and reduces AP events when used with a diet including ≤20 g fat per day. Tryngolza is self-administered once monthly via an autoinjector.

The FDA approval was based on data from the global, multicenter, randomized, placebo-controlled phase 3 Balance clinical trial involving adults with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. From baseline to six months, there was a significant placebo-adjusted mean reduction in triglyceride levels of 42.5 percent. From baseline to 12 months, reductions were further improved, with a placebo-adjusted 57 percent mean reduction in triglycerides. Over 12 months, there was a clinically meaningful reduction in AP events; one patient (5 percent) experienced one AP event in the Tryngolza group, compared with seven (30 percent) who experienced 11 episodes in the placebo group. A favorable safety profile was seen for Tryngolza.

"For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," Brett P. Monia, Ph.D., the chief executive officer of Ionis, said in a statement.

Approval of Tryngolza was granted to Ionis Pharmaceuticals.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-12-28 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords